Bg. Brown et al., Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N ENG J MED, 345(22), 2001, pp. 1583-1592
Citations number
39
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background: Both lipid-modifying therapy and antioxidant vitamins are thoug
ht to have benefit in patients with coronary disease. We studied simvastati
n-niacin and antioxidant-vitamin therapy, alone and together, for cardiovas
cular protection in patients with coronary disease and low plasma levels of
high-density lipoprotein (HDL) cholesterol.
Methods: In a three-year, double-blind trial, 160 patients with coronary di
sease, low HDL cholesterol levels, and normal low-density lipoprotein (LDL)
cholesterol levels were randomly assigned to receive one of four regimens:
simvastatin plus niacin, antioxidants, simvastatin-niacin plus antioxidant
s, or placebos. The end points were arteriographic evidence of a change in
coronary stenosis and the occurrence of a first cardiovascular event (death
, myocardial infarction, stroke, or revascularization).
Results: The mean levels of LDL and HDL cholesterol were unaltered in the a
ntioxidant group and the placebo group; these levels changed substantially
(by -42 percent and +26 percent, respectively) in the simvastatin-niacin gr
oup. The protective increase in HDL2 with simvastatin plus niacin was atten
uated by concurrent therapy with antioxidants. The average stenosis progres
sed by 3.9 percent with placebos, 1.8 percent with antioxidants (P=0.16 for
the comparison with the placebo group), and 0.7 percent with simvastatin-n
iacin plus antioxidants (P=0.004) and regressed by 0.4 percent with simvast
atin-niacin alone (P<0.001). The frequency of the clinical end point was 24
percent with placebos, 3 percent with simvastatin-niacin alone, 21 percent
in the antioxidant-therapy group, and 14 percent in the group given simvas
tatin-niacin plus antioxidants.
Conclusions: Simvastatin plus niacin provides marked clinical and angiograp
hically measurable benefits in patients with coronary disease and low HDL l
evels. The use of antioxidant vitamins in this setting must be questioned.
(N Engl J Med 2001;345:1583-92.) Copyright (C) 2001 Massachusetts Medical S
ociety.